Postmortem redistribution of the enantiomers of citalopram and its metabolites: An experimental study in rats

Journal of Analytical Toxicology

Volumn 28, Issue 8, 2004, Pages 631-637

  Kugelberg, Fredrik C ^a   Druid, Henrik ^b   Carlsson, Björn ^a   Ahlner, Johan ^a,c   Bengtsson, Finn ^a,d  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c National Board of Forensic Medicine   (Sweden)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DEMETHYLCITALOPRAM; DIDEMETHYLCITALOPRAM; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; OSMOTIC PUMP; RAT;

ANIMALIA;

EID: 8444223100     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/28.8.631     Document Type: Article

References (51)

1. B.G. Pollock. Citalopram: a comprehensive review. Expert Opin. Pharmacother. 2: 681-698 (2001).
2. J. Hyttel, K.P. Bøgesø, J. Perregaard, and C. Sánchez. The pharmacological effect of citalopram resides in the (S)-(+)- enantiomer. J. Neural. Transm. Gen. Sect. 88: 157-160 (1992).
3. M.J. Owens, D.L. Knight, and C.B. Nemeroff. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry 50: 345-350 (2001).
4. C. Sánchez, P.B.F. Bergqvist, L.T. Brennum, S. Gupta, S. Hogg, A. Larsen, and O. Wiborg. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl). 167: 353-362 (2003).
5. J. Waugh and K.L. Goa. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 17: 343-362 (2003).
6. E. Øyehaug, E.T. Østensen, and B. Salvesen. High-performance liquid chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients. J. Chromatogr. 308: 199-208 (1984).
7. J.T. Barbey and S.P. Roose. SSRI safety in overdose. J. Clin. Psychiatry 59: 42-48 (1998).
8. U. Lepola, E. Leinonen, and H. Koponen. Serum drug levels and electroencephalographic findings after citalopram intoxication. Nord. J. Psychiatry 50: 61-62 (1996).
9. M. Öström, A. Eriksson, J. Thorson, and O. Spigset. Fatal overdose with citalopram. Lancet 348: 339-340 (1996).
10. H. Druid and P. Holmgren. A compilation of fatal and control concentrations of drugs in postmortem femoral blood. J. Forensic Sci. 42: 79-87 (1997).
11. L. Grundemar, B. Wohlfart, C. Lagerstedt, F. Bengtsson, and G. Eklundh. Symptoms and signs of severe citalopram overdose. Lancet. 349: 1602 (1997).
12. M. Personne, G. Sjöberg, and H. Persson. Citalopram overdose - review of cases treated in Swedish hospitals. J. Toxicol. Clin. Toxicol. 35: 237-240 (1997).
13. K. Worm, C. Dragsholt, K. Simonsen, and B. Kringsholm. Citalopram concentrations in samples from autopsies and living persons. Int. J. Legal Med. 111: 188-190 (1998).
14. H.B. Rothenhäusler, C. Hoberl, S. Ehrentrout, H.P. Kapfhammer, and M.M. Weber. Suicide attempt by pure citalopram overdose causing long-lasting severe sinus bradycardia, hypotension and syncopes: successful therapy with a temporary pacemaker. Pharmacopsychiatry 33: 150-152 (2000).
15. C.A. Kelly, A. Upex, E.P. Spencer, R.J. Flanagan, and D.N. Bateman. Adult respiratory distress syndrome and renal failure associated with citalopram overdose. Hum. Exp. Toxicol. 22: 103-105 (2003).
16. K.M. Engebretsen, C.R. Harris, and J.E. Wood. Cardiotoxicity and late onset seizures with citalopram overdose. J. Emerg. Med. 25: 163-166 (2003).
17. D. Amital, H. Amital, R. Gross, S. Kindler, and J. Zohar. Sinus bradycardia due to fluvoxamine overdose. Br. J. Psychiatry 165: 553-554 (1994).
18. H. Druid and P. Holmgren. [A case report. Fatal case of acute fluoxetine poisoning]. Läkartidningen 93: 4149-4150 (1996).
19. D.H. Brendel, J.A. Bodkin, and J.M. Yang. Massive sertraline overdose. Ann. Emerg. Med. 36: 524-526 (2000).
20. F.C. Kugelberg, G. Apelqvist, B. Carlsson, J. Ahlner, and F. Bengtsson. In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats. Br. J. Pharmacol. 132: 1683-1690 (2001).
21. F.C. Kugelberg, B. Carlsson, J. Ahlner, and F. Bengtsson. Stereoselective single-dose kinetics of citalopram and its metabolites in rats. Chirality 15: 622-629 (2003).
22. P. Holmgren, B. Carlsson, A.L. Zackrisson, B. Lindblom, M.L. Dahl, M.G. Scordo, H. Druid, and J. Ahlner. Enantioselective analysis of citalopram and metabolites in postmortem blood and genotyping for CYP2D6 and CYP2C19. J. Anal. Toxicol. 28: 94-104 (2004).
23. D.J. Pounder and G.R. Jones. Post-mortem drug redistribution - a lexicological nightmare. Forensic Sci. Int. 45: 253-263 (1990).
24. T. Hilberg, Å. Ripel, L. Slørdal, A. Bjørneboe, and J. Mørland. The extent of postmortem drug redistribution in a rat model. J. Forensic Sci. 44: 956-962 (1999).
25. F. Bengtsson, M. Bugge, A. Brun, B. Falck, K.G. Henriksson, and A. Nobin. The impact of time after portacaval shunt in the rat on behavior, brain serotonin, and brain and muscle histology. J. Neurol. Sci. 83: 109-122 (1988).
26. B. Rochat, M. Amey, and P. Baumann. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther. Drug Monit. 17: 273-279 (1995).
27. B. Carlsson and B. Norlander. Optimization and characterization of the chiral separation of citalopram and its demethylated metabolites by response surface methodology. Chromatographia 53: 266-272 (2001).
28. B. Carlsson, G. Olsson, M. Reis, J. Wålinder, C. Nordin, J. Lundmark, M.G. Scordo, M.L. Dahl, F. Bengtsson, and J. Ahlner. Enantioselective analysis of citalopram and metabolites in adolescents. Ther. Drug Monit. 23: 658-664 (2001).
29. B. Carlsson and B. Norlander. Solid-phase extraction with end-capped C2 columns for the routine measurement of racemic citalopram and metabolites in plasma by high-performance liquid chromatography. J. Chromatogr. B 702: 234-239 (1997).
30. C. Wikell, G. Apelqvist, B. Carlsson, S. Hjorth, P.B.F. Bergqvist, F.C. Kugelberg, J. Ahlner, and F. Bengtsson. Pharmacokinetic and pharmacodynamic responses to chronic administration of the selective serotonin reuptake inhibitor citalopram in rats. Clin. Neuropharmacol. 22: 327-336 (1999).
31. F.C. Kugelberg, G. Apelqvist, and F. Bengtsson. Effects of chronic citalopram treatment on central and peripheral spontaneous open-field behaviours in rats. Pharmacol. Toxicol. 90: 303-310 (2002).
32. K. Fredricson Overø. Kinetics of citalopram in man; plasma levels in patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 6: 311-318 (1982).
33. D.B. Feldman and B.N. Gupta. Histopathologic changes in laboratory animals resulting from various methods of euthanasia. Lab. Anim. Sci. 26: 218-221 (1976).
34. W.R. Sawyer, D.R. Steup, B.S. Martin, and R.B. Forney. Cardiac blood pH as a possible indicator of postmortem interval. J. Forensic Sci. 33: 1439-1444 (1988).
35. R.W. Prouty and W.H. Anderson. The forensic science implications of site and temporal influences on postmortem blood-drug concentrations. J. Forensic Sci. 35: 243-270 (1990).
36. B. Levine, X. Zhang, J.E. Smialek, G.W. Kunsman, and M.E. Frontz. Citalopram distribution in postmortem cases. J. Anal. Toxicol. 25: 641-644 (2001).
37. A.J. Jenkins and K. Gubanich. Disposition of citalopram in biological specimens from postmortem cases. J. Forensic Sci. 47: 159-164 (2002).
38. N. Anastos, I.M. McIntyre, M.J. Lynch, and O.H. Drummer. Post-mortem concentrations of citalopram. J. Forensic Sci. 47: 882-884 (2002).
39. K. Fredricson Overø. Kinetics of citalopram in test animals; drug exposure in safety studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 6: 297-309 (1982).
40. T. Hilberg, A. Bugge, K.M. Beylich, J. Ingum, A. Bjørneboe, and J. Mørland. An animal model of postmortem amitriptyline redistribution. J. Forensic Sci. 38: 81-90 (1993).
41. T. Hilberg, J. Mørland, and A. Bjørneboe. Postmortem release of amitriptyline from the lungs; a mechanism of postmortem drug redistribution. Forensic Sci. Int. 64: 47-55 (1994).
42. G. Koren and S.M. MacLeod. Postmortem redistribution of digoxin in rats. J. Forensic Sci. 30: 92-96 (1985).
43. G. Koren and J. Klein. Postmortem redistribution of morphine in rats. Ther. Drug Monit. 14: 461-463 (1992).
44. B. Rochat, M. Amey, H. Van Gelderen, B. Testa, and P. Baumann. Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. Chirality 7: 389-395 (1995).
45. J.P. Foglia, B.G. Pollock, M.A. Kirshner, J. Rosen, R. Sweet, and B. Mulsant. Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol. Bull. 33: 109-112 (1997).
46. J. Sidhu, M. Priskorn, M. Poulsen, A. Segonzac, G. Grollier, and F. Larsen. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9: 686-692 (1997).
47. Z. Zheng, M. Jamour, and U. Klotz. Stereoselective HPLC-assay for citalopram and its metabolites. Ther. Drug Monit. 22: 219-224 (2000).
48. B. Rochat, M. Amey, M. Gillet, U.A. Meyer, and P. Baumann. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 7: 1-10 (1997).
49. O.V. Olesen and K. Linnet. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 59: 298-309 (1999).
50. K. Fu, R.J. Konrad, R.W. Hardy, R.M. Brissie, and C.A. Robinson. An unusual multiple drug intoxication case involving citalopram. J. Anal. Toxicol. 24: 648-650 (2000).
51. J. Kristinsson, T. Johannesson, O. Bjarnason, and G. Geirsson. Organ levels of amitriptyline and nortriptyline in fatal amitriptyline poisoning. Acta Pharmacol. Toxicol. (Copenh). 52: 150-152 (1983).